Argento, MD, senior clinical endocrinologist and diabetes technology director at the Maryland Endocrine and Diabetes Center, Columbia, Maryland, said that the trial was small but showed the benefit of using adjunctive therapy in T1D. There is an unmet need in patients with T1D with a high BMI and suboptimal glycemic control, he told Medscape Medical News Despite proven cardiorenal benefits of both GLP-1 agonists and SGLT2 inhibitors in type 2 diabetes, none are approved for use in T1D, which means that they are generally not covered by insurance. These medications end up being prohibitively expensive for those withT1D to access, Argento noted
Sermorelin's benefits are real but gradual
Four-pathway activation provides weight loss, metabolic improvement, and muscle pr
The procedures of animal study were approved by the Institutional Animal Care and Use Committee (IACUC2017O04) of National Laboratory Animal Center, National Applied Research Laboratories, Taiwan
doi: 10.1016/j.ccc.2021.05.003 5 XuZShiLWangYZhangJHuangLZhangCet al